Get the Stockscreener App
3.99
3.10%
0.12
After Hours:
3.91
-0.08
-2.01%
Prime Medicine Inc stock is traded at $3.99, with a volume of 4.45M.
It is up +3.10% in the last 24 hours and up +30.39% over the past month.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
See More
Previous Close:
$3.87
Open:
$3.83
24h Volume:
4.45M
Relative Volume:
1.68
Market Cap:
$720.66M
Revenue:
$4.63M
Net Income/Loss:
$-201.14M
P/E Ratio:
-2.9037
EPS:
-1.3741
Net Cash Flow:
$-167.10M
1W Performance:
+7.26%
1M Performance:
+30.39%
6M Performance:
+7.84%
1Y Performance:
+28.30%
1-Day Range:
$3.6595
$4.01
1-Week Range:
$3.61
$4.32
52-Week Range:
$2.67
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.99 | 666.48M | 4.63M | -201.14M | -167.10M | -1.3741 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Initiated | Oppenheimer | Outperform |
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Enterprise value to revenue forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
PRME Q1 2026 Earnings: EPS Misses Estimates but Stock Gains on Pipeline ProgressEarnings Decline Risk - dars.gov.et
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 2500 Growth Benchmark - marketscreener.com
Price to book forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
Prime Medicine, Inc.(NasdaqGM:PRME) added to Russell Microcap Growth Benchmark Index - marketscreener.com
H.C. Wainwright upgrades Prime Medicine stock rating to buy - Investing.com
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 2000 Growth Benchmark - marketscreener.com
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 3000E Growth Benchmark - marketscreener.com
Prime Medicine, Inc.(NasdaqGM:PRME) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Prime Medicine, Inc. Actuals & Estimates (NASDAQ:PRME) - TradingView
PRME Forecast — Price Target — Prediction for 2027 - TradingView
Prime Medicine Inc (PRME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Prime Medicine (PRME) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Prime Medicine Says PM359 Granted US FDA Regenerative Medicine Advanced Therapy Designation - Moomoo
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) - marketscreener.com
Prime Medicine Receives U.S. FDA Regenerative Medicine - GlobeNewswire
Citizens reiterates Prime Medicine stock rating on gene therapy focus By Investing.com - Investing.com South Africa
Citizens reiterates Prime Medicine stock rating on gene therapy focus - Investing.com
Prime Medicine’s CGD therapy gets FDA RMAT, speeding review - Stock Titan
Prime Medicine, Inc. (PRME) reports Q1 loss, misses revenue estimates - MSN
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL) - The Globe and Mail
Prime Medicine’s PM-577a cleared for clinic for Wilson’s disease - BioWorld News
Prime Medicine receives clearance for first in vivo gene therapy trial - Investing.com Canada
Prime Medicine receives clearance for first in vivo gene therapy trial By Investing.com - Investing.com India
Prime Medicine Announces New Zealand Clearance of Clinical - GlobeNewswire
Prime Medicine Inc (PRME) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prime Medicine Inc (PRME) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ocular Therapeutix vs Prime Medicine: Two Paths in Medical Innovation - HarianBasis.co
Prime Medicine Inc (PRME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Prime Medicine Inc (PRME) Institutional Confidence - TradingKey
Prime Medicine Inc (PRME) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prime Medicine Inc (PRME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation StocksNews and Statistics - IndexBox
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
PRME Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Development ProgramsEPS Guidance Update - newsline.com
Prime Medicine's Prime Editing Is Worth The Risk (NASDAQ:PRME) - Seeking Alpha
Prime Drink Group announces private placement up to C$2.2M By Investing.com - Investing.com Australia
Prime Drink Group announces private placement up to C$2.2M - Investing.com UK
Prime Medicine (PRME) Holds Steady Near Support as Gene Editing Stock Seeks DirectionBlue Chip Entry Points - newsline.com
PRME Price Today: Prime Medicine, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Transcript : Prime Medicine, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
Prime Medicine Stockholders Reaffirm Board and Auditor Choices - The Globe and Mail
Prime Medicine (PRME) awards director David Schenkein 75,000 stock options - Stock Titan
Prime Medicine (PRME) director receives 75,000 options at $3.06 - Stock Titan
Prime Medicine (PRME) director and 10% owner receives 75,000-share option grant - Stock Titan
Prime Medicine (PRME) director receives 75,000-share stock option grant - Stock Titan
Prime Medicine (PRME) awards director 75,000 stock options at $3.06 - Stock Titan
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prime Medicine Inc Stock (PRME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):